Document is current

Article History

First Online: 19 February 2026

Competing interests

: C.C. reports grants from Intercept Pharmaceuticals and Arrow Génériques, and consulting work for Cymabay, Gilead, Ipsen, Calliditas, GSK, Mirum, Advanz, Echosens and Intercept Pharmaceuticals. M.-C.L. reports grants from Gilead and Mirum, consulting work for Advanz, Mirum, Gilead, Ipsen, Falk and GSK, and lectures for Advanz, GSK, Gilead and Ipsen. H.Y. reports participation in advisory board for Ipsen and congress participation by invitation from Ipsen. A.V. reports speaker fees from Intercept. A.T. reports consultant work for GSK, Kowa, Kaken Pharmaceuticals, Ipsen, Mirum, Abbvie and Gilead. U.B. reports consulting and/or lecture fees from Abacus, Amgen, Behring, GSK, Ipsen, Mirum, Ono.